Huntsville, Alabama — Glaukos Corp, a developer of ophthalmic pharmaceuticals and medical technologies, kicked off a project to open a new, state-of-the-art research, development and manufacturing facility in Huntsville.
The project, located on 25 acres Cummings Research Park, will feature a 200,000-square-foot advanced facility dedicated to developing novel therapies for glaucoma, corneal disorders and retinal diseases.
California-based Glaukos said it plans to invest over $80 million in the multi-year effort, which is expected to create more than 150 full-time jobs. The company also holds an option for future expansion on 15 additional acres.
Thomas Burns, Glaukos Chairman and CEO, said, “After evaluating over 100 potential sites worldwide, we ultimately chose Huntsville for its strong talent base and vibrant business climate."
“We appreciate our new partnership with the City of Huntsville and look forward to the ophthalmic innovations that will emerge from this strategic expansion as we continue advancing our mission to transform vision therapies for patients living with chronic eye diseases,” he added.
Glaukos expects to complete construction on the new facility by 2030, with hiring and operations scaling up in tandem.
